Return on Equity (ROE): 66.94%
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 66.94% is in line with its 5-year average of 61.90%, around the middle of its 5-year range (43.90%–82.92%).
As of Saturday, June 27, 2026. 17.43% below its 12-month average of 81.07%.
NRC Return on Equity (ROE) Chart
Annual fiscal-year return on equity; no daily interpolation.
NRC Average Return on Equity (ROE) Chart
NRC Current vs Average Return on Equity (ROE) Chart
NRC Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
66.94%
RETURN ON EQUITY (ROE) AVG TTM
81.07%
RETURN ON EQUITY (ROE) AVG 3Y
67.39%
RETURN ON EQUITY (ROE) AVG 5Y
61.90%
RETURN ON EQUITY (ROE) AVG 10Y
63.76%
RETURN ON EQUITY (ROE) AVG 15Y
43.40%
RETURN ON EQUITY (ROE) AVG 20Y
36.89%
CURRENT VS TTM AVG
-17.43%
CURRENT VS 3Y AVG
-0.66%
CURRENT VS 5Y AVG
+8.15%
CURRENT VS 10Y AVG
+4.99%
CURRENT VS 15Y AVG
+54.23%
CURRENT VS 20Y AVG
+81.46%
NRC Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| National Research Corporation (NRC) | $468.99M | 66.94% | 81.07% | 67.39% | 61.90% |
| Shoulder Innovations, Inc. (SI)vs › | $472.62M | -33.14% | -52.50% | -47.15% | -47.15% |
| 23andMe Holding Co. (ME)vs › | $15.31M | -721.75% | 348.35% | 157.32% | 61.09% |
| Teladoc Health, Inc. (TDOC)vs › | $1.51B | -12.81% | -40.81% | -170.75% | -114.78% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.21B | -47.65% | -45.75% | -30.11% | -18.95% |
| TransMedics Group, Inc. (TMDX)vs › | $2.37B | 34.80% | 27.86% | 4.54% | -12.45% |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.56B | -2.97% | 25.09% | 5.57% | 0.40% |
| Oscar Health, Inc. (OSCR)vs › | $7.72B | -2.37% | -21.41% | -36.14% | -25.75% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $8.13B | 2.46% | -8.94% | -15.72% | 1.14% |
| Universal Health Services, Inc. (UHS)vs › | $9.12B | 20.19% | 18.80% | 15.17% | 15.31% |
Return Analysis
ROE
66.9%
ROA
6.7%
Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for National Research Corporation (NRC)?
- The return on equity (ROE) for NRC stock is 66.94%.
- Is National Research Corporation's return on equity (ROE) high or low?
- The return on equity (ROE) of 66.94% is in line with its 5-year average of 61.90%, around the middle of its 5-year range (43.90%–82.92%).
- What is the TTM average return on equity (ROE) for National Research Corporation (NRC)?
- The TTM average return on equity (ROE) for NRC stock is 81.07%.
- What is the 3Y average return on equity (ROE) for National Research Corporation (NRC)?
- The 3Y average return on equity (ROE) for NRC stock is 67.39%.
- What is the 5Y average return on equity (ROE) for National Research Corporation (NRC)?
- The 5Y average return on equity (ROE) for NRC stock is 61.90%.
- What is the 10Y average return on equity (ROE) for National Research Corporation (NRC)?
- The 10Y average return on equity (ROE) for NRC stock is 63.76%.
- What is the 15Y average return on equity (ROE) for National Research Corporation (NRC)?
- The 15Y average return on equity (ROE) for NRC stock is 43.40%.
- What is the 20Y average return on equity (ROE) for National Research Corporation (NRC)?
- The 20Y average return on equity (ROE) for NRC stock is 36.89%.
NRC Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 82.92% |
| 2024-12-31 | 79.22% |
| 2023-12-31 | 63.26% |
| 2022-12-31 | 44.15% |
| 2021-12-31 | 43.90% |
| 2020-12-31 | 57.93% |
| 2019-12-31 | 98.52% |
| 2018-12-31 | 157.45% |
| 2017-12-31 | 25.48% |
| 2016-12-31 | 24.78% |
| 2015-12-31 | 23.73% |
| 2014-12-31 | 20.69% |
| 2013-12-31 | 21.58% |
| 2012-12-31 | 26.56% |
| 2011-12-31 | 20.82% |
| 2010-12-31 | 17.49% |
| 2009-12-31 | 19.22% |
| 2008-12-31 | 19.29% |
| 2007-12-31 | 16.17% |
| 2006-12-31 | 16.01% |
| 2005-12-31 | 16.06% |
| 2004-12-31 | 13.00% |
| 2003-12-31 | 13.52% |
| 2002-12-31 | 13.74% |
| 2001-12-31 | 7.15% |
| 2000-12-31 | 12.71% |
| 1999-12-31 | 8.06% |
| 1998-12-31 | 2.87% |
| 1997-12-31 | 17.68% |
| 1996-12-31 | 109.52% |
Related Metrics
About National Research Corporation
National Research Corporation (NRC) empowers healthcare organizations across the United States and Canada with data-driven analytics and actionable insights to enhance both patient and employee experiences. Through a comprehensive suite of subscription-based solutions, NRC supplies crucial information and analysis, addressing vital aspects such as the overall patient journey, service recovery initiatives, effective transitions of care, health risk assessments, fostering employee engagement, and enhancing reputation management and brand loyalty. Beyond these, NRC provides market intelligence to help organizations understand brand awareness, public perception, and competitive positioning. They offer advanced segmentation tools to analyze community needs, wants, and behaviors in real-time. Specialized health risk assessment tools are available to help clients pinpoint and support high-risk populations, fostering preventative care strategies and wellness initiatives. Similarly, transition management solutions assist in identifying and managing at-risk patients during care changes, aiming to reduce readmissions and ensure smooth, satisfactory transitions. NRC also offers transparency tools, empowering healthcare providers to present clear organizational information to consumers, thereby supporting informed decision-making. Furthermore, governance solutions are tailored for the leadership of non-profit hospitals and health systems, including boards of directors, executives, and physician leaders. Their clientele includes integrated health systems, post-acute care providers, and healthcare payer organizations. Established in 1981, National Research Corporation maintains its headquarters in Lincoln, Nebraska.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Trent Green